Alembic rejigs domestic thrust and readies for global generics expansion
This article was originally published in Scrip
Executive Summary
Alembic Pharmaceuticals of India is making a conscious shift to chase growth in the chronic and lifestyle segments of the domestic formulations market while de-emphasising the anti-infectives segment, a traditional stronghold. It is also readying for a larger play in the international generics business, as capacity expansions and product approvals roll in.